<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118507</article-id><article-id pub-id-type="publisher-id">ACM-44579</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_34255651.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群对代谢综合征相关性脑卒中影响的研究进展
  Research Progress on the Influence of Gut Microbiota on Metabolic Syndrome-Associated Stroke
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>常慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>晁</surname><given-names>倩</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宫</surname><given-names>健伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>莱山区滨州医学院康复医学院，山东 烟台</addr-line></aff><aff id="aff3"><addr-line>峄城区中医院康复科，山东 枣庄</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3481</fpage><lpage>3486</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  代谢综合征(Metabolic syndrome, MS)作为脑卒中的关键高危因素可显著增加脑卒中的患病率及死亡率。众多研究表明，肠道菌群和脑卒中及代谢综合征之间存在着密切的联系。本文将脑卒中和代谢综合征视为一个复合的整体，综述代谢综合征相关性脑卒中患者的肠道菌群对其疾病的影响以及相关性研究进展。
   Metabolic syndrome, as a key factor of stroke, can significantly increase the prevalence and mortality of stroke. Numerous studies have shown a close link between intestinal bacteria and stroke and metabolic syndrome. In this paper, stroke and metabolic syndrome are regarded as a composite whole, and the effect of intestinal bacteria on the disease and the related research progress of stroke patients with metabolic syndrome are reviewed.
 
</p></abstract><kwd-group><kwd>肠道菌群，脑卒中，代谢综合征，粪菌移植, Gut Microbiota</kwd><kwd> Stroke</kwd><kwd> Metabolic Syndrome</kwd><kwd> Fecal Microbiota Transplants</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>代谢综合征(Metabolic syndrome, MS)作为脑卒中的关键高危因素可显著增加脑卒中的患病率及死亡率。众多研究表明，肠道菌群和脑卒中及代谢综合征之间存在着密切的联系。本文将脑卒中和代谢综合征视为一个复合的整体，综述代谢综合征相关性脑卒中患者的肠道菌群对其疾病的影响以及相关性研究进展。</p></sec><sec id="s2"><title>关键词</title><p>肠道菌群，脑卒中，代谢综合征，粪菌移植</p></sec><sec id="s3"><title>Research Progress on the Influence of Gut Microbiota on Metabolic Syndrome-Associated Stroke<sup> </sup></title><p>Changhui Yang<sup>1</sup>, Qian Chao<sup>2</sup>, Jianwei Gong<sup>1</sup></p><p><sup>1</sup>College of Rehabilitation Medicine, Binzhou Medical University, Laishan District, Yantai Shandong</p><p><sup>2</sup>Rehabilitation Department, Yicheng District Hospital of Traditional Chinese Medicine, Zaozhuang Shandong</p><p><img src="//html.hanspub.org/file/24-1572492x4_hanspub.png?20210817170939094" /></p><p>Received: Jul. 11<sup>th</sup>, 2021; accepted: Aug. 10<sup>th</sup>, 2021; published: Aug. 17<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/24-1572492x5_hanspub.png?20210817170939094" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Metabolic syndrome, as a key factor of stroke, can significantly increase the prevalence and mortality of stroke. Numerous studies have shown a close link between intestinal bacteria and stroke and metabolic syndrome. In this paper, stroke and metabolic syndrome are regarded as a composite whole, and the effect of intestinal bacteria on the disease and the related research progress of stroke patients with metabolic syndrome are reviewed.</p><p>Keywords:Gut Microbiota, Stroke, Metabolic Syndrome, Fecal Microbiota Transplants</p><disp-formula id="hanspub.44579-formula2"><graphic xlink:href="//html.hanspub.org/file/24-1572492x6_hanspub.png?20210817170939094"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/24-1572492x7_hanspub.png?20210817170939094" /> <img src="//html.hanspub.org/file/24-1572492x8_hanspub.png?20210817170939094" /></p></sec><sec id="s5"><title>1. 引言</title><p>近15年来，我国脑卒中的发病率和患病率呈明显上升趋势，且发病率、患病率、死亡率和伤残调整寿命年均持续高于英美日等发达国家的同期水平 [<xref ref-type="bibr" rid="hanspub.44579-ref1">1</xref>]。据统计，我国脑卒中的发病风险为39.9%，相当于每5个人中就有2个是脑卒中患者，同时每年大约有196万人死于脑卒中 [<xref ref-type="bibr" rid="hanspub.44579-ref2">2</xref>]。导致脑卒中发病的危险因素包括不可干预性和可干预性两类，不可干预性危险因素包括年龄、性别、遗传等；可干预性危险因素主要包括肥胖、糖尿病、高血压、高血脂、动脉粥样硬化、血栓形成、心脏病、抽烟、饮酒、缺乏运动等，是卒中预防及降低发病率的主要干预对象。MS是心脑血管疾病的多种代谢危险因素在个体内的集结状态，主要包括肥胖、糖尿病、高血压等 [<xref ref-type="bibr" rid="hanspub.44579-ref3">3</xref>]。相关研究显示，41%的脑血管病患者同时患有MS，且脑卒中合并MS患者的死亡率是不合并MS患者的5~6倍 [<xref ref-type="bibr" rid="hanspub.44579-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44579-ref5">5</xref>]。既往研究都特别重视MS的核心机制胰岛素抵抗，而近些年来随着学者们对肠道菌群研究的不断深入，越来越多的证据支持肠道菌群与MS之间存在着紧密的联系 [<xref ref-type="bibr" rid="hanspub.44579-ref6">6</xref>]。本文将脑卒中和MS视为一个复合的整体，综述MS相关性脑卒中患者的肠道菌群对其疾病的影响以及相关性研究进展。</p></sec><sec id="s6"><title>2. 肠道菌群及肠道菌群失调</title><p>肠道菌群是指分布在整个胃肠道的微生物群落，主要由两个优势细菌门组成，拟杆菌门和厚壁菌门约占总数的90%以上，其它的次优势菌门包括变形菌门、放线菌门和梭杆菌门等 [<xref ref-type="bibr" rid="hanspub.44579-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44579-ref8">8</xref>]。肠道菌群能够通过对抗病原体、调节机体代谢、参与肠道屏障及免疫系统的形成，维护机体的内环境稳态及健康，因此又被称为内分泌及免疫器官 [<xref ref-type="bibr" rid="hanspub.44579-ref9">9</xref>]。</p><p>正常生理状态下，肠道菌群与机体保持着一种互利互惠的动态平衡。人本身的遗传基因、生活习惯、以及罹患各种疾病等因素都会引起肠道菌群的改变。微生物紊乱主要表现在肠道微生物群在种类、数量、比例、定位和生物学特性的变化 [<xref ref-type="bibr" rid="hanspub.44579-ref10">10</xref>]。肠道菌群的组成与变化可以和人类的许多疾病联系起来，例如菌群失调不仅会导致腹泻、便秘等消化系统的功能紊乱，还可通过内分泌系统、免疫系统、神经系统等多种途径引起全身性的病理反应，影响肠外疾病的发生发展，包括肾病、免疫系统疾病、神经系统疾病、心血管疾病等。总之，肠道菌群和人体的健康和疾病关系密切。</p></sec><sec id="s7"><title>3. 代谢综合征与脑卒中</title><p>脑卒中具有高发病率、高复发率、高致残率、高死亡率的特点，给社会造成了沉重的负担，俨然已成为亟需解决的重大公共卫生问题。因此，研究脑卒中的预防及控制，形势异常严峻。MS作为包含脑卒中多重高危因素的聚集症候群，引发了人们对慢性代谢性疾病以及危险因素聚集的关注和重视。Kazlauskienė等 [<xref ref-type="bibr" rid="hanspub.44579-ref11">11</xref>] 研究表明，MS患者发生卒中的风险为非MS患者的2倍多，并且随着危险因素的增加，脑卒中的发病风险会逐渐增大。同时脑卒中合并MS患者卒中复发的风险比非MS患者高43% [<xref ref-type="bibr" rid="hanspub.44579-ref12">12</xref>]。事实上，随着年龄的增长，MS的各个成分之间相互作用，促进机体代谢紊乱加重，导致脑血管动脉粥样硬化病变，进一步促进脑缺血的发生、缺血性脑组织面积的扩大以及阻碍血管再通的进程，影响脑卒中的发生及复发。因此，针对MS各成分进行积极有效的干预是脑卒中预防和治疗的重要策略。</p></sec><sec id="s8"><title>4. 菌群失调与代谢综合征</title><p>MS作为一组复杂的代谢紊乱症候群，不仅是脑卒中的独立高危因素，也是复发性脑卒中的强预测因子。尽管过去关于MS的定义有很多个标签，且代谢异常成分尚未完全统一，但目前学者们普遍认同代谢综合征是指人体内的蛋白质、脂肪、碳水化合物等物质发生代谢紊乱的病理状态，通常表现为肥胖、高血糖、高血压等。</p><sec id="s8_1"><title>4.1. 菌群失调与肥胖</title><p>肥胖作为MS的始动因素，已经成为一种全球范围内的流行病，因此针对肥胖症病因的研究也在不断的涌现。肠道菌群作为一个相对较新的影响因素，发挥着不可忽视的作用。Zuo等 [<xref ref-type="bibr" rid="hanspub.44579-ref13">13</xref>] 2011年在国内开展的一项关于肥胖人群肠道菌群的临床研究表明，肥胖组产气荚膜梭菌和拟杆菌的含量较正常组明显降低。相关的动物实验也是层出不穷，一项经典的动物研究表明，在同种富含脂多糖饮食的情况下，遗传性肥胖小鼠、瘦小鼠和野生型小鼠相比，肥胖小鼠的肠道菌群中厚壁菌门的丰度相对增加，拟杆菌门的相对丰度降低 [<xref ref-type="bibr" rid="hanspub.44579-ref14">14</xref>]。另外，学者们也注意到，尽管无菌(GF)小鼠的热量摄入较高，但它们似乎对高脂饮食喂养所导致的体重增加具有抵抗力，因为它们的体重远不及常规小鼠。有趣的是，通过对GF小鼠进行粪菌移植研究表明，与接受瘦供体移植的GF小鼠相比，接受肥胖供体移植的GF小鼠的体重增加更多，这表明肥胖表型可通过菌群移植而传播 [<xref ref-type="bibr" rid="hanspub.44579-ref15">15</xref>]。总之，上述研究均支持肠道菌群改变和肥胖有着不可分割的关系，但菌群失调是肥胖的“因”还是“果”尚无明确定论。</p><p>近年来，肠道菌群以及菌群来源的脂多糖(LPS，又称内毒素)介导的慢性低度炎症在肥胖症的发病机制中的作用逐渐引起了大家的关注。LPS是革兰氏阴性菌外膜的主要成分，也是典型的炎症诱导物质 [<xref ref-type="bibr" rid="hanspub.44579-ref16">16</xref>]，可引发代谢性内毒素血症。高脂饮食使血浆LPS水平增加5倍 [<xref ref-type="bibr" rid="hanspub.44579-ref17">17</xref>]。另外也有研究提出肠道菌群可通过内源性大麻素(eCB)系统参与能量稳态、食欲调节、胃肠动力和炎症反应的调节，在肥胖及相关代谢内毒素血症中发挥作用 [<xref ref-type="bibr" rid="hanspub.44579-ref18">18</xref>]。</p></sec><sec id="s8_2"><title>4.2. 菌群失调与糖尿病</title><p>临床中90%~95%的糖尿病患者为2型糖尿病(T2DM)，其本质是进行性胰岛β细胞功能丧失及胰岛素抵抗引起的一组糖代谢异常的多因素疾病，受遗传、饮食及多种环境因素的共同影响。事实上不论是关于糖尿病的动物实验还是临床试验，都有充分的证据表明肠道菌群在T2DM的发生发展中有着密切的联系。Li等 [<xref ref-type="bibr" rid="hanspub.44579-ref19">19</xref>] 对比40只T2DM组SD大鼠和正常组SD大鼠发现，T2DM组SD大鼠肠道内的大肠杆菌和肠球菌明显高于正常组，而T2DM组的双歧杆菌和乳酸杆菌明显低于正常组。通过给糖尿病小鼠补充益生元来改善肠道菌群失调情况后发现，患者的葡萄糖耐量和低度炎症反应明显改善 [<xref ref-type="bibr" rid="hanspub.44579-ref20">20</xref>]。另一项临床研究表明 [<xref ref-type="bibr" rid="hanspub.44579-ref21">21</xref>]，与非糖尿病患者相比，T2DM患者的肠道菌群状态为中度肠道生态紊乱，肠道内一些产丁酸盐的细菌丰度普遍降低，如罗氏菌属、柔嫩梭菌等。多种条件致病菌丰度增加，如梭菌、梭状芽孢杆菌等，同时一些硫酸盐还原反应、抗氧化应激等微生物功能也有所增强，进而引起胰岛素抵抗和血糖升高 [<xref ref-type="bibr" rid="hanspub.44579-ref22">22</xref>]。</p><p>尽管肠道菌群失调诱发T2DM的机制尚未完全阐明，但学者们普遍认同的一个机制是肠道菌群代谢产物短链脂肪酸(SCFA)系统，它是由结肠中的菌群发酵膳食纤维和抗性淀粉所产生，主要包括乙酸盐、丙酸盐和丁酸盐 [<xref ref-type="bibr" rid="hanspub.44579-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.44579-ref23">23</xref>]。研究发现，糖尿病患者肠道中产SCFAs的菌群减少，进而导致SCFAs的含量下降 [<xref ref-type="bibr" rid="hanspub.44579-ref24">24</xref>]。SCFAs能够通过多种机制引起胰岛细胞功能受损，导致胰岛素敏感性降低和胰岛素抵抗。它主要的作用机制包括：1) SCFAs可通过激活G蛋白偶联受体(GPCRs)家族调控胰腺β细胞分泌胰岛素以及肠上皮L细胞分泌PYY和GLP-1，导致糖代谢和脂代谢异常。2) 肠道中低水平的SCFAs导致组蛋白去乙酰化酶(HDAC)的抑制作用减弱以及诱导T细胞转化为调节性T细胞的能力减弱，引起促炎因子(如IL-8、TNF-α)和抗炎因子(如IL-10)的分泌失衡，导致慢性低度炎症，加速糖尿病的进程 [<xref ref-type="bibr" rid="hanspub.44579-ref25">25</xref>]。</p></sec><sec id="s8_3"><title>4.3. 菌群失调与高血压</title><p>高血压是公认的脑卒中最重要的危险因素，关于肠道菌群参与血压调节的报道早在1982年就有相关研究提出 [<xref ref-type="bibr" rid="hanspub.44579-ref26">26</xref>]，近年来更是有大量研究阐述了肠道菌群及其代谢产物影响高血压的进程。Yang等 [<xref ref-type="bibr" rid="hanspub.44579-ref27">27</xref>] 进行的一项动物实验表明，与正常小鼠的对比发现，在自发性高血压大鼠以及慢性血管紧张素II输注导致的高血压大鼠模型中，均观察到肠道菌群的数量及丰度显著降低，F/B比显著增加，且产乙酸盐和丁酸盐的菌群丰度减少、产乳酸盐的菌群体丰度增加。临床研究显示 [<xref ref-type="bibr" rid="hanspub.44579-ref28">28</xref>]，在高血压前期和高血压人群中，微生物丰度和多样性均显著降低，并且进一步发现了可能对高血压前期及高血压人群最具有鉴别能力的菌群——普雷沃氏菌，肠道菌群分布的差异揭示了高血压前期和高血压人群肠道微生物群落结构的深刻变化，暗示了肠道微生物在高血压发展中的意义。</p><p>既往研究表明，肠道菌群及其代谢产物可以通过调节肠道代谢、胃肠和肾脏离子转运以及盐敏感性来影响血压，这些机制当中研究的相对较为透彻的为短链脂肪酸系统(SCFAs) [<xref ref-type="bibr" rid="hanspub.44579-ref29">29</xref>]。血液中的SCFAs主要通过作用于血管平滑肌细胞上的嗅觉受体78 (Olfr78)和蛋白偶联受体41 (Gpr41)这两种受体来影响血压，SCFAs作用于Olfr78升高血压，作用于Gpr41降低血压。正常情况下，升压和降压作用处于一种动态平衡状态，当菌群失调，SCFAs含量异常时，平衡被打破，导致血压的异常。另一个关键的菌群代谢产物胆汁酸也可直接与宿主相互作用而影响血压。初级胆汁酸在肠道内经菌群加工成次级胆汁酸后，可通过激活胆汁酸受体、法呢样X受体(FXR)等来影响心血管功能 [<xref ref-type="bibr" rid="hanspub.44579-ref30">30</xref>]。其次高盐饮食也可通过诱导肠道菌群依赖的辅助性T-17细胞导致高血压 [<xref ref-type="bibr" rid="hanspub.44579-ref31">31</xref>]。</p><p>尽管肠道微生物群是一个新的不断发展的领域，但目前的证据强烈支持肠道菌群在人体代谢及神经系统中的整体作用。肠道菌群及其代谢产物可通过多种途径影响宿主的能量代谢、胆汁酸代谢、胰岛素抵抗、食欲调节及肠道屏障完整性等，每一条途径都可能为菌群干预的精准靶向治疗提供新的视角。</p></sec></sec><sec id="s9"><title>5. 菌群失调与脑卒中</title><p>肠道菌群与脑卒中的交流是一种双向通讯信号通路。众多研究表明肠道菌群可通过多种途径影响脑卒中的危险因素，作用于脑卒中的发生发展过程。除了上文所描述的作用机制外，肠道菌群还可通过其代谢产物氧化三甲胺(TMAO)影响血小板高反应性和介导泡沫细胞形成促进动脉粥样硬化的产生，增加脑卒中的风险性 [<xref ref-type="bibr" rid="hanspub.44579-ref20">20</xref>]。Benakis等 [<xref ref-type="bibr" rid="hanspub.44579-ref10">10</xref>] 研究表明，经过抗生素预处理后的脑卒中小鼠脑梗死面积减少60%，说明肠道菌群在一定程度上可以通过抗炎作用来影响脑卒中的预后。另一方面，卒中后大脑也可通过多种途径作用于肠道菌群。其中一种途径是中风后应激反应导致肠道蠕动减少，菌群失调。另外，应激反应还可通过作用于下丘脑–垂体–肾上腺轴增加肠道通透性，从而导致肠道菌群易位增加，引发脑卒中后常见的并发症卒中后感染 [<xref ref-type="bibr" rid="hanspub.44579-ref10">10</xref>]。</p></sec><sec id="s10"><title>6. 粪菌移植</title><p>到目前为止，益生菌和益生元是使用最广泛的通过调节肠道菌群而改善代谢失衡的策略，但很多新近研究支持粪菌移植(FMT)是调节肠道菌群更为有效的方法。FMT疗法是将健康供体的粪便制剂注入患者的胃肠道内，直接改变受者胃肠道的菌群成分，以恢复肠道菌群正常的结构和功能 [<xref ref-type="bibr" rid="hanspub.44579-ref32">32</xref>]。FMT以能够有效治疗复发性艰难梭菌感染而闻名，目前被实验性用于治疗胃肠疾病(如炎症性肠病、肠易激综合征等)以及胃肠道以外的疾病(如慢性疲劳综合征、帕金森病等) [<xref ref-type="bibr" rid="hanspub.44579-ref33">33</xref>]。一项通过FMT疗法治疗代谢综合征的临床试验表明，受试者的胰岛素敏感性在接受治疗后有一定程度的改善 [<xref ref-type="bibr" rid="hanspub.44579-ref34">34</xref>]，但迄今为止，关于FMT治疗脑卒中的临床案例尚无报道，仅有部分动物实验表明FMT可改善脑卒中的预后。除此之外，FMT也存在一些潜在的风险，例如FMT的长期效果尚不明确，可能会引起传染病的传播，以及腹泻、发烧等一些轻微的症状 [<xref ref-type="bibr" rid="hanspub.44579-ref35">35</xref>]。因此，针对FMT安全性、有效性及可行性的评估仍有很长的路程要走。</p></sec><sec id="s11"><title>7. 小结与展望</title><p>近年来，随着对肠道菌群研究的不断深入，其在慢性代谢性疾病以及脑卒中的预防和治疗中的价值也逐渐地凸现。以肠道菌群为靶点的新兴治疗方法：抗生素干预、微生态制剂以及粪便菌群移植等治疗方式给MS以及脑卒中患者的预防和治疗带来了很大的希望。尽管如此，肠道菌群与脑卒中合并MS之间的作用机制仍未完全阐明，以肠道菌群作为治疗靶点的临床研究仍处于起步阶段，其在人类脑卒中患者中应用的安全性和有效性也是未知的，未来仍需要我们用大量的动物及临床研究来探索评估的。</p></sec><sec id="s12"><title>文章引用</title><p>杨常慧,晁 倩,宫健伟. 肠道菌群对代谢综合征相关性脑卒中影响的研究进展Research Progress on the Influence of Gut Microbiota on Metabolic Syndrome-Associated Stroke[J]. 临床医学进展, 2021, 11(08): 3481-3486. https://doi.org/10.12677/ACM.2021.118507</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44579-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">王亚楠, 吴思缈, 刘鸣. 中国脑卒中15年变化趋势和特点[J]. 华西医学, 2021, 36(6): 803-807.</mixed-citation></ref><ref id="hanspub.44579-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">《中国脑卒中防治报告》编写组. 《中国脑卒中防治报告2019》概要[J]. 中国脑血管病杂志, 2020, 17(5): 272-281.</mixed-citation></ref><ref id="hanspub.44579-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张培培, 张祥建, 高硕君. 肠道菌群失调可增加脑卒中风险[J]. 中华神经科杂志, 2017, 50(10): 781-785.</mixed-citation></ref><ref id="hanspub.44579-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">刘伟, 方黎, 江选东, 李中秋. 老年急性脑梗死合并代谢综合征患者的认知损伤表现分析[J]. 中国实用神经疾病杂志, 2014, 17(22): 26-27, 28.</mixed-citation></ref><ref id="hanspub.44579-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">石强. 脑梗死合并代谢综合征的临床特征及预后分析[J]. 实用临床医药杂志, 2015, 19(15): 14-17.</mixed-citation></ref><ref id="hanspub.44579-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mazidi, M., Rezaie, P., Kengne, A.P., Mobarhan, M.G. and Ferns, G.A. (2016) Gut Microbiome and Metabolic Syndrome. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews, 10, S150-S157.  
&lt;br&gt;https://doi.org/10.1016/j.dsx.2016.01.024</mixed-citation></ref><ref id="hanspub.44579-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mariat, D., Firmesse, O., Levenez, F., Guimarăes, V.D., Sokol, H, Doré, J., et al. (2009) The Firmicutes/Bacteroidetes Ratio of the Human Microbiota Changes with Age. BMC Microbiology, 9, Article No. 123.  
&lt;br&gt;https://doi.org/10.1186/1471-2180-9-123</mixed-citation></ref><ref id="hanspub.44579-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva Datchary, P., et al. (2015) Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell Host &amp; Microbe, 17, 690-703.  
&lt;br&gt;https://doi.org/10.1016/j.chom.2015.04.004</mixed-citation></ref><ref id="hanspub.44579-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Winek, K., Meisel, A. and Dirnagl, U. (2016) Gut Microbiota Impact on Stroke Outcome: Fad or Fact? Journal of Cerebral Blood Flow &amp; Metabolism, 36, 891-898. &lt;br&gt;https://doi.org/10.1177%2F0271678X16636890</mixed-citation></ref><ref id="hanspub.44579-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tan, B.Y.Q., Paliwal, P.R. and Sharma, V.K. (2020) Gut Microbiota and Stroke. Annals of Indian Academy of Neurology, 23, 155-158.</mixed-citation></ref><ref id="hanspub.44579-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kazlauskienė, L., Butnorienė, J. and Norkus, A. (2015) Metabolic Syndrome Related to Cardiovascular Events in a 10-Year Prospective Study. Diabetology &amp; Metabolic Syndrome, 7, Article No. 102.  
&lt;br&gt;https://doi.org/10.1186/s13098-015-0096-2</mixed-citation></ref><ref id="hanspub.44579-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fang, X., Liu, H., Zhang, X., Zhang, H., Qin, X. and Ji, X. (2016) Metabolic Syndrome, Its Components, and Diabetes on 5-Year Risk of Recurrent Stroke among Mild-to-Moderate Ischemic Stroke Survivors: A Multiclinic Registry Study. Journal of Stroke and Cerebrovascular Diseases, 25, 626-634.  
&lt;br&gt;https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.017</mixed-citation></ref><ref id="hanspub.44579-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zuo, H.J., Xie, Z.M., Zhang, W.W., Li, Y.-R., Wang, W., Ding, X.-B., et al. (2011) Gut Bacteria Alteration in Obese People and Its Relationship with Gene Polymorphism. World Journal of Gastroenterology, 17, 1076-1081.</mixed-citation></ref><ref id="hanspub.44579-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tseng, C.H. and Wu, C.Y. (2019) The Gut Microbiome in Obesity. Journal of the Formosan Medical Association, 118, S3-S9. &lt;br&gt;https://doi.org/10.1016/j.jfma.2018.07.009</mixed-citation></ref><ref id="hanspub.44579-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lee, C.J., Sears, C.L. and Maruthur, N. (2020) Gut Microbiome and Its Role in Obesity and Insulin Resistance. Annals of the New York Academy of Sciences, 1461, 37-52. &lt;br&gt;https://doi.org/10.1111/nyas.14107</mixed-citation></ref><ref id="hanspub.44579-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Liu, L., Cao, Z., Li, W., Li, H., Lu, C., et al. (2020) Gut Microbiota as an “Invisible Organ” That Modulates the Function of Drugs. Biomedicine &amp; Pharmacotherapy, 121, Article ID: 109653.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2019.109653</mixed-citation></ref><ref id="hanspub.44579-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., et al. (2007) Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes, 56, 1761-1772. &lt;br&gt;https://doi.org/10.2337/db06-1491</mixed-citation></ref><ref id="hanspub.44579-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Zhang, H. and Wang, G. (2020) Correlations between Inflammatory Response, Oxidative Stress, Intestinal Pathological Damage and Intestinal Flora Variation in Rats with Type 2 Diabetes Mellitus. European Review for Medical and Pharmacological Sciences, 24, 10163-10168.</mixed-citation></ref><ref id="hanspub.44579-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Silva, Y.P., Bernardi, A. and Frozza, R.L. (2020) The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Frontiers in Endocrinology, 11, Article No. 25. &lt;br&gt;https://doi.org/10.3389/fendo.2020.00025</mixed-citation></ref><ref id="hanspub.44579-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., et al. (2016) Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell, 165, 111-124. &lt;br&gt;https://doi.org/10.1016/j.cell.2016.02.011</mixed-citation></ref><ref id="hanspub.44579-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., et al. (2012) A Metagenome-Wide Association Study of gut Microbiota in Type 2 Diabetes. Nature, 490, 55-60. &lt;br&gt;https://doi.org/10.1038/nature11450</mixed-citation></ref><ref id="hanspub.44579-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">陈诚, 陆明, 夏娟, 陈琳, 雷涛. 肠道菌群与2型糖尿病关系的研究进展[J]. 医学综述, 2017, 23(15): 3072-3076.</mixed-citation></ref><ref id="hanspub.44579-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Canfora, E.E., Meex, R.C.R., Venema, K. and Blaak, E.E. (2019) Gut Microbial Metabolites in Obesity, NAFLD and T2DM. Nature Reviews. Endocrinology, 15, 261-273. &lt;br&gt;https://doi.org/10.1038/s41574-019-0156-z</mixed-citation></ref><ref id="hanspub.44579-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C.J., Fagerberg, B., et al. (2013) Gut Metagenome in European Women with Normal, Impaired and Diabetic Glucose Control. Nature, 498, 99-103.  
&lt;br&gt;https://doi.org/10.1038/nature12198</mixed-citation></ref><ref id="hanspub.44579-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Q., Li, Y., Li, P., Wang, M., Tang, Z., Wang, T., et al. (2019) Research Progress in the Relationship between Type 2 Diabetes Mellitus and Intestinal Flora. Biomedicine &amp; Pharmacotherapy, 117, Article ID: 109138.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2019.109138</mixed-citation></ref><ref id="hanspub.44579-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Honour, J. (1982) The Possible Involvement of Intestinal Bacteria in Steroidal Hypertension. Endocrinology, 110, 285-287. &lt;br&gt;https://doi.org/10.1210/endo-110-1-285</mixed-citation></ref><ref id="hanspub.44579-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yang, T., Santisteban, M.M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J.M., et al. (2015) Gut Dysbiosis Is Linked to Hypertension. Hypertension, 65, 1331-1340. &lt;br&gt;https://doi.org/10.1161/HYPERTENSIONAHA.115.05315</mixed-citation></ref><ref id="hanspub.44579-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., et al. (2017) Gut Microbiota Dysbiosis Contributes to the Development of Hypertension. Microbiome, 5, Article No. 14. &lt;br&gt;https://doi.org/10.1186/s40168-016-0222-x</mixed-citation></ref><ref id="hanspub.44579-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Jose, P.A. and Raj, D. (2015) Gut Microbiota in Hypertension. Current Opinion in Nephrology and Hypertension, 24, 403-409. &lt;br&gt;https://doi.org/10.1097/MNH.0000000000000149</mixed-citation></ref><ref id="hanspub.44579-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Yang, X., Zhou, X. and Cai, J. (2021) The Role and Mechanism of Intestinal Flora in Blood Pressure Regulation and Hypertension Development. Antioxidants &amp; Redox Signaling, 34, 811-830. &lt;br&gt;https://doi.org/10.1089/ars.2020.8104</mixed-citation></ref><ref id="hanspub.44579-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wilck, N., Matus, M.G., Kearney, S.M., Olesen, S.W., Forslund, K., Bartolomaeus, H., et al. (2017) Salt-Responsive Gut Commensal Modulates TH17 Axis and Disease. Nature, 551, 585-589. &lt;br&gt;https://doi.org/10.1038/nature24628</mixed-citation></ref><ref id="hanspub.44579-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., et al. (2019) Fecal Microbiota Transplantation: Review and Update. Journal of the Formosan Medical Association, 118, S23-S31.  
&lt;br&gt;https://doi.org/10.1016/j.jfma.2018.08.011</mixed-citation></ref><ref id="hanspub.44579-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Adak, A. and Khan, M.R. (2019) An Insight into Gut Microbiota and Its Functionalities. Cellular and Molecular Life Sciences, 76, 473-493. &lt;br&gt;https://doi.org/10.1007/s00018-018-2943-4</mixed-citation></ref><ref id="hanspub.44579-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Smits, L.P., Kootte, R.S., Levin, E., Prodan, A., Fuentes, S., Zoetendal, E.G., et al. (2018) Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients with Metabolic Syndrome. Journal of the American Heart Association, 7, Article No. e008342.  
&lt;br&gt;https://doi.org/10.1161/JAHA.117.008342</mixed-citation></ref><ref id="hanspub.44579-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Torres-Fuentes, C., Schellekens, H., Dinan, T.G. and Cryan, J.F. (2017) The Microbiota-Gut-Brain Axis in Obesity. Lancet Gastroenterology &amp; Hepatology, 2, 747-756. &lt;br&gt;https://doi.org/10.1016/S2468-1253(17)30147-4</mixed-citation></ref></ref-list></back></article>